Department of Family and Community Medicine, Saint Louis University School of Medicine, Missouri, USA.
Harry S. Truman Veterans Administration Medical Center, Columbia, Missouri, USA.
J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):1436-1443. doi: 10.1093/gerona/glab115.
Adult vaccinations may reduce risk for dementia. However, it has not been established whether tetanus, diphtheria, pertussis (Tdap) vaccination is associated with incident dementia.
Hypotheses were tested in a Veterans Health Affairs (VHA) cohort and replicated in a MarketScan medical claims cohort. Patients were at least 65 years of age and free of dementia for 2 years prior to index date. Patients either had or did not have a Tdap vaccination by the start of either of the 2 index periods (2011 or 2012). Follow-up continued through 2018. Controls had no Tdap vaccination for the duration of follow-up. Confounding was controlled using entropy balancing. Competing risk (VHA) and Cox proportional hazard (MarketScan) models estimated the association between Tdap vaccination and incident dementia in all patients and age subgroups (65-69, 70-74, and ≥75 years).
VHA patients were, on average, 75.6 (SD ± 7.5) years of age, 4% female, and 91.2% were White. MarketScan patients were 69.8 (SD ± 5.6) years of age, on average and 65.4% were female. After controlling for confounding, patients with, compared to without, Tdap vaccination had a significantly lower risk for dementia in both cohorts (VHA: hazard ratio [HR] = 0.58; 95% confidence interval [CI]:0.54-0.63 and MarketScan: HR = 0.58; 95% CI:0.48-0.70).
Tdap vaccination was associated with a 42% lower dementia risk in 2 cohorts with different clinical and sociodemographic characteristics. Several vaccine types are linked to decreased dementia risk, suggesting that these associations are due to nonspecific effects on inflammation rather than vaccine-induced pathogen-specific protective effects.
成人疫苗接种可能降低痴呆风险。然而,尚未确定破伤风、白喉、百日咳(Tdap)疫苗接种是否与痴呆的发生有关。
在退伍军人事务部(VA)队列中检验了假设,并在 MarketScan 医疗索赔队列中进行了复制。患者年龄至少为 65 岁,在索引日期前 2 年内没有痴呆。患者要么在 2011 年或 2012 年的任何一个索引期开始时都接种了 Tdap 疫苗,要么都没有接种。随访持续到 2018 年。对照者在整个随访期间都没有接种 Tdap 疫苗。使用熵平衡控制混杂。在所有患者和年龄亚组(65-69 岁、70-74 岁和≥75 岁)中,竞争风险(VA)和 Cox 比例风险(MarketScan)模型估计了 Tdap 疫苗接种与痴呆发生之间的关联。
VA 患者的平均年龄为 75.6(标准差 ± 7.5)岁,4%为女性,91.2%为白人。MarketScan 患者的平均年龄为 69.8(标准差 ± 5.6)岁,65.4%为女性。在控制混杂因素后,与未接种 Tdap 疫苗的患者相比,接种 Tdap 疫苗的患者在两个队列中痴呆风险显著降低(VA:风险比 [HR] = 0.58;95%置信区间 [CI]:0.54-0.63 和 MarketScan:HR = 0.58;95% CI:0.48-0.70)。
在具有不同临床和社会人口统计学特征的 2 个队列中,Tdap 疫苗接种与痴呆风险降低 42%相关。几种疫苗类型与痴呆风险降低有关,这表明这些关联是由于炎症的非特异性影响,而不是疫苗诱导的针对病原体的特异性保护作用。